Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied by GlobalData

 in association with


Netherlands Embracing Generics to Counter Growing Healthcare Costs

With the elderly making up an ever greater share of the country’s population, the Netherlands is increasingly supporting its generics sector in an attempt to address mounting healthcare costs, says a new report from industry experts GlobalData.

The firm’s latest publication — Healthcare, Regulatory and Reimbursement Landscape — Netherlands — shows that the percentage of Dutch citizens aged 65 and over has climbed from 14.1% in 2006 to 15.6% last year, and is expected to further increase to 18.6% by the end of the decade – unavoidably increasing the demand on the nation’s healthcare resources.

In a bid to cut the country’s healthcare deficit, the Netherlands is focusing on the use of generics as a cost-containment tool. In 2008, health insurers introduced preference policies, which contain lists of medicines that have the same composition (or active substance), but differ in price. This resulted from health insurers’ preference to reimbursing these less expensive medications. Consequently, the prices of commonly-used generic drugs fell by an average of 85% the following year.

In addition, the government allowed insurers to add biosimilar drugs in their preference policies in 2009, providing further momentum to the country’s expanding generics market.

Thanks in part to this system, the generic pharmaceutical market in the Netherlands increased in value from US$832m in 2005 to an estimated US$1.8 billion in 2010, at a Compound Annual Growth Rate (CAGR) of 15%.

With several major drugs going off-patent in the near future, GlobalData expects the Dutch generics sector to continue its impressive expansion, providing fantastic opportunities for the country’s generics manufacturers.

See the report:
Healthcare, Regulatory and Reimbursement Landscape - Netherlands


GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.


All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.


Free Sample Pages

Published: November 2012, Reference code: GDHC0030CHR

Report Price: $1995 (Single User License)


To top



To top